Direct intraperitoneal insemination in ovarian hyperstimulation cycles induced with gonadotropin-releasing hormone agonist.
Direct intraperitoneal insemination (DIPI) is one of the least invasive strategies of assisted reproduction. Unexplained infertility, cervical factors and male sub-fertility are major indications for DIPI. This is a report of pregnancy that occurred as a result of a novel trial of DIPI, in which ovarian stimulation took place using a long gonadotropin-releasing hormone (GnRH) analogue and human menopausal gonadotropin (HMG) protocol in a patient who had been unsuccessfully treated with intrauterine insemination.
Misao
R
R
Department of Obstetrics and Gynecology, Gifu University School of Medicine, Japan.
Itoh
M
M
Nakanishi
Y
Y
Tamaya
T
T
D000328:Adult; D002064:Buserelin / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D005300:Fertility Agents, Female / Q000009:adverse effects / Q000627:therapeutic use*; D007987:Gonadotropin-Releasing Hormone / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use*; D006801:Humans; D007247:Infertility, Female / Q000628:therapy*; D007317:Insemination, Artificial, Homologous / Q000379:methods*; D008297:Male; D008596:Menotropins / Q000009:adverse effects / Q000627:therapeutic use*; D016471:Ovarian Hyperstimulation Syndrome / Q000139:chemically induced / Q000503:physiopathology; D010062:Ovulation Induction / Q000379:methods*; D011247:Pregnancy; D013480:Superovulation; D016896:Treatment Outcome
D005300:Fertility Agents, Female; D007987:Gonadotropin-Releasing Hormone; D008596:Menotropins; D002064:Buserelin